C4-spiro-pyrrolidine antivirals

A compound represented by Formula (I):

• or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof, wherein:
• M at each occurrence is selected from the group consisting of:
• a) —OR1;
• b) —NR1R2;
• and
• c) -R1;
• wherein R1 and R2 at each occurrence are each independently selected from the group consisting of:
• 1. hydrogen;
• 2. deuterium;
• 3. -R3;
• Wherein R3 at each occurrence is selected from the group consisting of:
• 1)-C1-C8 alkyl, —C2-C8 alkenyl, —C2-C8 alkynyl or —C3-C8 cycloalkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;
• 2) substituted —C1-C8 alkyl, substituted —C2-C8 alkenyl, substituted —C2-C8 alkynyl or substituted —C3-C8 cycloalkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;
• 3) heterocyclic;
• 4) substituted heterocyclic;
• 5) aryl;
• 6) substituted aryl;
• 7) heteroaryl;
• and
• 8) substituted heteroaryl;
• or R1 and R2 taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted heterocyclic group;
• Q at each occurrence is selected from the group consisting of:
• a) —R1;
• b) —C(O)R1;
• c) —C(O)OR1;
• d) —C(O)NR1R2;
• e) —S(O)nR1, wherein n=0, 1, or 2;
• f) —S(O)mNR1R2, m=1 or 2;
• g) —(C═NR4)NR1R2, wherein R4 is independently R1;
• h) —P(O)R1R2;
• i) —P(O)(OR1)(OR2);
• j) —P(O)(NR1R2)(NR2R4);
• and
• k) —P(O)(NR1R2)(OR4);
• X and Y taken together with the carbon atom to which they are attached form a group consisting of:
• a) substituted or unsubstituted C3-C8-cycloalkyl group;
• b) substituted or unsubstituted C3-C8-cycloalkenyl group;
• and
• c) substituted or unsubstituted heterocyclic group;
• Z and J at each occurrence are each independently —R3.